Cargando…

Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient

Detalles Bibliográficos
Autores principales:	Quaglino, Pietro, Fava, Paolo, Cariti, Caterina, Ortoncelli, Michela, Aimetti, Mario, Milan, Alberto, Dapavo, Paolo, Tonella, Luca, Ribero, Simone, Fierro, Maria Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Libbey Eurotext 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880629/ https://www.ncbi.nlm.nih.gov/pubmed/33262101 http://dx.doi.org/10.1684/ejd.2020.3925

Ejemplares similares

Treatment of Advanced Metastatic Melanoma
por: Quaglino, Pietro, et al.
Publicado: (2021)

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives
por: Roccuzzo, Gabriele, et al.
Publicado: (2021)

Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study
por: Mastorino, Luca, et al.
Publicado: (2022)

Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study
por: Gullo, Giulia, et al.
Publicado: (2022)

Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit
por: Quaglino, Pietro, et al.
Publicado: (2021)

Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
por: Mastorino, Luca, et al.
Publicado: (2022)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022)

Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials
por: Amabile, Simone, et al.
Publicado: (2021)

Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience
por: Cariti, Caterina, et al.
Publicado: (2021)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
por: REPETTO, Federica, et al.
Publicado: (2022)

CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study
por: Quaglino, Pietro, et al.
Publicado: (2022)

In Vivo Observation of Cutaneous Larva Migrans by Fluorescence-Advanced Videodermatoscopy
por: Ramondetta, Alice, et al.
Publicado: (2021)

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs
por: Burzi, Lorenza, et al.
Publicado: (2022)

Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients
por: Mastorino, Luca, et al.
Publicado: (2022)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Time to next treatment and safety assessment in cutaneous‐T‐cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Alopecia areata after COVID-19 vaccination
por: Gallo, Giuseppe, et al.
Publicado: (2022)

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
por: REPETTO, Federica, et al.
Publicado: (2023)

The Skin Microbiome and Its Role in Psoriasis: A Review
por: Celoria, Valentina, et al.
Publicado: (2023)

Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?
por: Mastorino, Luca, et al.
Publicado: (2022)

Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
por: MASTORINO, Luca, et al.
Publicado: (2022)

Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors
por: RAMONDETTA, Alice, et al.
Publicado: (2020)

Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications
por: Tonella, Luca, et al.
Publicado: (2021)

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study
por: Mastorino, Luca, et al.
Publicado: (2021)

Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study
por: Amabile, Simone, et al.
Publicado: (2022)

Immunotherapy in transplanted patients: A special population that can no longer be ignored
por: Rubatto, Marco, et al.
Publicado: (2021)

Exploring Psoriasis Inflammatory Microenvironment by NanoString Technologies
por: Ricci, Alessia Andrea, et al.
Publicado: (2023)

Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis
por: Miniotti, Marco, et al.
Publicado: (2022)

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
por: Liberini, Virginia, et al.
Publicado: (2021)

Sézary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
por: Rubatto, Marco, et al.
Publicado: (2023)

Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report
por: Gelato, Federica, et al.
Publicado: (2022)

Cutaneous Events Associated with Immunotherapy of Melanoma: A Review
por: Burzi, Lorenza, et al.
Publicado: (2021)

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2021)

Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2022)

A Case of a Pigmented Epithelioid Melanocytoma on a Mucosal Site
por: Ramondetta, Alice, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gup8pgen6ufsu8nk7ohshcv0n4